Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fipamezole for neurogenic orthostatic hypotension in multiple system atrophy or Parkinson's disease
2007-004890-24Phase 2Active
- Sponsor
- Juvantia
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fipamezole in Neurogenic Orthostatic Hypotension (nOH) (2 arms), sponsored by Juvantia. Primary endpoint: Difference in maximal orthostatic systolic blood pressure fall. Started May 2008; status: active.
02
Drugs
fipamezole
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2007-004890-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004890-24.